Last reviewed · How we verify

Pipracil — Competitive Intelligence Brief

Pipracil (Piperacillin Sodium) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Penicillin-class antibacterial with beta-lactamase inhibitor.

marketed Penicillin-class antibacterial with beta-lactamase inhibitor Beta-lactamase producing bacteria Small molecule Live · refreshed every 30 min

Target snapshot

Pipracil (Piperacillin Sodium) — Pfizer Inc.. Piperacillin and tazobactam is an antibacterial drug combination.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Pipracil TARGET Piperacillin Sodium Pfizer Inc. marketed Penicillin-class antibacterial with beta-lactamase inhibitor Beta-lactamase producing bacteria 1981-01-01
Piperacillin And Tazobactam Piperacillin Sodium Pfizer marketed Penicillin-class antibacterial with beta-lactamase inhibitor Bacterial cell wall; beta-lactamase enzyme 1981-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Penicillin-class antibacterial with beta-lactamase inhibitor class)

  1. Pfizer · 1 drug in this class
  2. Pfizer Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Pipracil — Competitive Intelligence Brief. https://druglandscape.com/ci/zosyn-in-plastic-container. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: